By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.




CEO: Richard A. Gonzalez

CFO: William J. Chase


Please click here for Abbvie job opportunities.


Please click here for clinical trial information..


Key Statistics

Ownership: Public

Web Site: AbbVie
Symbol: ABBV

Company News
AbbVie (ABBV) And Bristol-Myers Squibb (BMY) Announce Clinical Research Collaboration To Evaluate A Therapeutic Regimen In Advanced Solid Tumors 9/22/2017 6:23:46 AM
AbbVie (ABBV) Announces Positive Topline Results From Phase III Trial Evaluating VENCLEXTA/VENCLYXTO (Venetoclax) Tablets In Combination With Rituxan (Rituximab) For The Treatment Of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia 9/18/2017 9:58:33 AM
Two Deaths Hit AbbVie (ABBV)'s Late-Stage RA Study 9/11/2017 6:52:06 AM
AbbVie (ABBV) Declares Quarterly Dividend 9/8/2017 6:43:44 AM
AbbVie (ABBV) Leads Biotechnology Industry On Dow Jones Sustainability Index For Second Consecutive Year 9/7/2017 9:38:51 AM
AbbVie (ABBV)'s Upadacitinib (ABT-494) Meets Primary Endpoint In Phase IIb Study In Atopic Dermatitis 9/7/2017 6:37:48 AM
Inventiva And AbbVie (ABBV) Extend Agreement To Discover New Potent Orally-Available Small Molecule Ror? Inverse Agonist Drug Candidates 9/6/2017 12:10:39 PM
AbbVie (ABBV) Submits New Drug Application To U.S. FDA For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain 9/6/2017 6:39:24 AM
AbbVie Canada Release: More Canadians Have Access To HUMIRA (Adalimumab) For The Treatment Of Ulcerative Colitis (UC) 8/29/2017 8:48:35 AM
Why Investors Love AbbVie (ABBV) 8/28/2017 7:16:00 AM